Cargando…

Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost

BACKGROUND: Authors from the Canadian Agency for Drugs and Technologies in Health (CADTH) presented an analysis of submissions to the Common Drug Review (CDR) between 2004 and February 3, 2016 for drugs for rare disorders (disorders with a prevalence of <50 per 100,000). OBJECTIVE: The aim of thi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rawson, Nigel S. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363033/ https://www.ncbi.nlm.nih.gov/pubmed/28330479 http://dx.doi.org/10.1186/s13023-017-0611-7

Ejemplares similares

Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
por: Rawson, Nigel S. B.
Publicado: (2022)

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
por: Hoch, Jeffrey S., et al.
Publicado: (2015)

Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand
por: Rawson, Nigel S. B.
Publicado: (2020)

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada
por: Ji, Hezhao, et al.
Publicado: (2018)

New Delhi Metallo-β-Lactamase, Ontario, Canada
por: Tijet, Nathalie, et al.
Publicado: (2011)

Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?
por: Rawson, Nigel SB, et al.
Publicado: (2017)

National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare"
por: Rawson, Nigel S. B.
Publicado: (2020)

Can a population study assess the impact of fetal monitoring technology?
por: Kessler, Jørg, et al.
Publicado: (2022)

Promoting adherence to medicines: possible lessons for Canada?
por: Rawson, Nigel S. B.
Publicado: (2017)

“Impact of COVID-19 on lifestyle habits and mental health symptoms in children with attention-deficit/hyperactivity disorder in Canada”: Can we trust the numbers from this Internet survey?
por: LeBlanc, John C
Publicado: (2021)

Cost effective assay choice for rare disease study designs
por: Campbell, Desmond D, et al.
Publicado: (2015)

The Cost of Drugs
Publicado: (1905)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Ethmocephaly: A rare cephalic disorder
por: Dewan, Pooja, et al.
Publicado: (2016)

Impact of Quantitative Assessment of Parkinson’s Disease-Associated Symptoms Using Wearable Technology on Treatment Decisions
por: Carroll, Camille, et al.
Publicado: (2019)

Hypoparathyroidism in a case of Wilson's disease: Rare association of a rare disorder
por: Fatima, Jalees, et al.
Publicado: (2013)

Epilepsy Care- Awarness, Cost and Availability of Antiepileptic Drugs
por: Shubhakaran, Khichar
Publicado: (2021)

Obsessive-compulsive disorder of vowels (rare type)
por: Ghorpade, V. Anandprakash
Publicado: (2009)

Rare tumor – insulinoma mimicking dissociative disorder
por: Agarwal, Supriya, et al.
Publicado: (2020)

Klebsiella pneumoniae Carbapenemase, Canada
por: Pillai, Dylan R., et al.
Publicado: (2009)

Rat-bite Fever, Canada
por: Schachter, Michael E., et al.
Publicado: (2006)

Technological Solutions to Address Drug-Resistant Neisseria gonorrhoeae
por: Bristow, Claire C., et al.
Publicado: (2016)

Technology-enabled remote management of diabetes foot disease and potential for reduction in associated health costs: a pilot study
por: Main, Fiona, et al.
Publicado: (2021)

Role of the Health Technology Assessment in Revising Health Insurance Benefits Package: Guiding or Shaping?
por: NOUHI, Mojtaba, et al.
Publicado: (2020)

Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder
por: Li, Ming, et al.
Publicado: (2019)

Deliberate paradigm shift in research in rare neurodevelopmental disorders
por: Bain, Jennifer M., et al.
Publicado: (2021)

Pseudo-neonatal Adrenoleukodystrophy: A Rare Peroxisomal Disorder
por: Arora, Cheshta, et al.
Publicado: (2022)

Rare diseases and orphan drugs: 500 years ago
por: Dooms, Marc M.
Publicado: (2015)

Preparation of IMGs for Residency Training in Canada
por: Duncan, Andrew, et al.
Publicado: (2012)

Surgical management of primary hyperparathyroidism in Canada
por: Williams, Blair A, et al.
Publicado: (2014)

New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

EPIDEMIOLOGICAL FINDINGS ON THE PREVALENCE OF MENTAL DISORDER IN INDIA
por: Sureshkumar, P.N.
Publicado: (2000)

Revisiting the public health implications of the United States–Mexico– Canada agreement
por: Adekola, Tolulope Anthony
Publicado: (2020)

A cost-effective cadaveric model for plastic surgery simulation
por: Ng, Nigel Yong Boon, et al.
Publicado: (2016)

Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed()()()()
por: Finsterer, Josef, et al.
Publicado: (2017)

Neuroacanthocytosis: A rare movement disorder with magnetic resonance imaging
por: Gautam, G, et al.
Publicado: (2011)

Monilethrix, a rare inherited hair shaft disorder in siblings
por: Vora, Rita V, et al.
Publicado: (2014)

A rare case of modafinil dependence presenting as sleep disorder
por: Samudra, Madhura, et al.
Publicado: (2021)

Anesthetic management of patients with Morvan syndrome – A rare disorder
por: Singh, Shelly, et al.
Publicado: (2023)

High Prevalence of Rare Mutations in the Beta Globin Gene in an Ethnic Group in Iran
por: Galehdari, H, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ioqd1oguo5b37n35k81ocbjbjj